A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago

Table 4 Unadjusted and age-adjusted associations (hazard ratio) between Wave 1 HHV-8 seropositivity and prostate cancer at Wave 2 or Wave 3, overall and within strata defined by Wave 1 prostate cancer screening test results

Wave 1 prostate cancer screening test result	Cases		Sub-cohort		Unadjusted		Age-adjusted
	Pos	n	Pos	n	HR	95% CI	HR	95% CI
Overall	17	96	46	415	1.46	0.78-2.74	0.88¹	0.46-1.69
PSA (ng/mL)
< 4	12	70	39	392	1.61	0.77-3.38	1.03¹	0.49-2.16
≥ 4	5	26	7	23	0.44	0.11-1.71	0.39²	0.10-1.63
DRE positive or PSA ≥ 4 ng/mL
no	9	54	32	345	1.67	0.72-3.86	1.02¹	0.44-2.39
yes	8	42	14	70	0.85	0.52-2.38	0.59³	0.18-1.91

Pos - number HHV-8 positive, n - case or sub-cohort count, HR - hazard ratio, CI - confidence interval, PSA - prostate-specific antigen, DRE - digital rectal examination
1. Adjusted across four age categories: 40-44, 45-49, 50-59, ≥ 60 years
2. Adjusted across two age categories: 40-59, ≥ 60 years
3. Adjusted across three age categories: 40-49, 50-59, ≥ 60 years

ISSN: 1750-9378